FDA agrees on Abivax’s pediatric study plan to develop obefazimod for children with IBD

The FDA has agreed on Abivax’s initial pediatric study plan for the development of obefazimod in children aged 2 to 17 years with inflammatory bowel disease, the company announced in a press release.In October 2022, Abivax enrolled its first patient in ABTECT, a phase 3 program with obefazimod in adults with moderate to severe ulcerative colitis. With that program underway, Abivax initiated plans to develop obefazimod for children with IBD, starting with UC, the release stated.“The FDA agreement on the pediatric plan for obefazimod in IBD is an important step for Abivax toRead More

Generated by Feedzy